News

Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen’s research is developed by Roche. The compound is similar to the

Sanofi-aventis said that separate injections are being used by people following a basal-bolus insulin of a basal insulin and a mealtime insulin. The regimen is designed to address

Vpriv is Shire’s enzyme replacement therapy (ERT) for the treatment of type 1 Gaucher disease. Shire said that the CHMP positive opinion is expected to be forwarded to

Under the terms of the agreement, Lydall will provide Shrink with certain quantities of its Solupore thermoplastic membrane for the purpose of conducting a one-year research and development

Spherix said that reduction of triglyceride levels is a secondary endpoint of the Phase 3 trial. Results from the trial are expected later this summer. Spherix’s unblinded Phase

Octreolin is an oral form of octreotide acetate that uses the company’s proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly. Chiasma said that if

Brinavess is an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. Merck and Cardiome Pharma said that the

Under the terms of agreement, Grifols takes a further step towards the consolidation of its diagnostic division, expanding its range of products with the immunohematology technology. Progenika and

In Cell Art’s ICAntibodies is an integrated process for antigen design, nanocarriers/DNA formulation and genetic immunisation in mice, rats and rabbits. In the absence of recombinant protein, In